Ribozyme Pharmaceuticals, Inc. Demonstrates Potent Activity Of A Ribozyme Targeted Against The Hepatitis C Virus

Presented at Amer. Assoc. for the Study of Liver Diseases Conference

BOULDER, Colorado, November 9, 1998 -- Ribozyme Pharmaceuticals, Inc. (RPI) (Nasdaq: RZYM) today announced that HEPTAZYME®, a ribozyme designed to selectively destroy Hepatitis C Virus (HCV) RNA, was effective in decreasing Hepatitis C Viral RNA in cell culture assays. This work was presented at the American Association for the Study of Liver Diseases (AASLD) conference in Chicago by Dr. Lawrence Blatt, RPI's Senior Director of Biopharmacology and Preclinical Research. In these studies, HEPTAZYME® demonstrated significant inhibition of the HCV viral translation process in cells at very low doses, and in a manner that implies applicability across multiple forms of the virus.

Hepatitis C Virus (HCV) is the most common chronic bloodborne infection in the United States today. A recent Centers for Disease Control report stated that over 4 million Americans are chronically infected with HCV, and it is estimated that 500 million people are infected with HCV worldwide. The disease, which is more common than HIV, kills 8,000-10,000 Americans annually, and the death toll is expected to triple over the next 10-20 years. Furthermore, development of effective treatments has been hampered by the presence of multiple forms of HCV, with at least six genotypes and more than 90 subtypes known.

HEPTAZYME® contains many novel features believed to be important for HCV treatment. First, HEPTAZYME® is a ribozyme, a catalytic RNA molecule that has the unique potential to bind and cleave HCV RNA specifically and selectively, thus suggesting that viral replication can be inhibited without affecting other normal physiological processes. Next, HEPTAZYME® cleaves the HCV RNA at a location that is completely conserved in all known genotypes and subtypes of HCV, which gives HEPTAZYME® the potential to inhibit all forms of the virus. Finally, since HCV replicates in the cytoplas

Contact: Neil Cohen
415-677-4455 x. 205
Noonan/Russo Communications

Page: 1 2 3

Related biology news :

1. Ribozyme package effective against hepatitis B virus
2. Ribozymes Come Ready For Action
3. Ribozymes To The Rescue: New UF Gene Therapy Shows Promise For Treatment Of Inherited Blindness
4. Interdisciplinary Method Offers New Way To Study Ribozymes
5. Vion Demonstrates Readiness Of First Tumor-Targeting Salmonella For Human Testing Against Solid Tumors
6. Engineering Animation, Inc. Demonstrates Internet Anatomy At Visible Human Project Conference
7. Study Demonstrates High Conservation Potential Of Logged Rainforest
8. Potential for enhanced sequestration of carbon in soils supports evaluations
9. Potent toxin reveals new antibiotic resistance mechanism
10. Potential blood test for colon cancer risk
11. Potential new treatment for Gaucher disease developed by scientists at Scripps Research Institute

Post Your Comments:

(Date:5/9/2019)... (PRWEB) , ... May 09, 2019 , ... ... of its first suite of products based on its microbubble technology. Unlike magnetic-based ... simply float to the surface. Feedback from customers who participated in an early ...
(Date:5/8/2019)... , ... May 08, 2019 , ... ... Real-Time Metrics (“Axiom”), a premier provider of unified eClinical solutions and services that ... trials and observational studies. Axiom is a leading e-clinical technology company that focuses ...
(Date:5/2/2019)... ... April 30, 2019 , ... Philadelphia intellectual property law firm ... Gunes Bender, Ph.D., a registered patent agent, has joined the firm as a ... Bender provides technical support and scientific expertise in the pharmaceutical and biotechnical arts ...
Breaking Biology News(10 mins):
(Date:5/4/2019)... ... May 03, 2019 , ... ... the Diopsys® ffERG/Photopic Negative Response vision test, a new full field ... it is estimated that 6.3 million Americans will have glaucoma, with black Americans ...
(Date:5/2/2019)... ... May 02, 2019 , ... Researchers ... present results documenting discrepancies between U.S. insurer policies for genetic testing and the ... for hereditary breast and ovarian cancer (HBOC). , Jill S. Dolinsky, ...
(Date:4/18/2019)... Mass. (PRWEB) , ... April 18, 2019 , ... ... fossil fuels, a research team that includes a chemical engineer at Worcester Polytechnic ... exotic microorganism that may make it possible to manufacture isobutanol and other biofuels ...
(Date:4/12/2019)... JUPITER, Fla. (PRWEB) , ... April 12, 2019 ... ... will explore recent developments in neurotechnology and will educate about innovative tools and ... 3Q/2019. Check your local listings for more information. , This segment of Advancements ...
Breaking Biology Technology:
Cached News: